Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$43.03 USD
+0.05 (0.12%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $43.02 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IONS 43.03 +0.05(0.12%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
Other News for IONS
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target to $64 | IONS Stock News
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Ionis Pharmaceuticals (IONS) Receives Analyst Upgrade and Price Target Increase | IONS Stock News
IONS Stock Update: HC Wainwright & Co. Raises Price Target to $65.00 | IONS Stock News